Patents by Inventor Simon Charles Cruwys
Simon Charles Cruwys has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20210371513Abstract: Binding members, e.g. human antibody molecules, which bind interleukin-6 (IL-6) and neutralise its biological effects. Use of binding members for IL-6 in medical treatment e.g. for treating inflammatory diseases and tumours associated with IL-6.Type: ApplicationFiled: April 9, 2021Publication date: December 2, 2021Inventors: Simon Charles Cruwys, Steven Godfrey Lane, Philip Mallinder
-
Publication number: 20200079845Abstract: Binding members, e.g. human antibody molecules, which bind interleukin-6 (IL-6) and neutralise its biological effects. Use of binding members for IL-6 in medical treatment e.g. for treating inflammatory diseases and tumours associated with IL-6.Type: ApplicationFiled: March 21, 2019Publication date: March 12, 2020Inventors: Simon Charles Cruwys, Steven Godfrey Lane, Philip Mallinder
-
Publication number: 20180162936Abstract: Binding members, e.g. human antibody molecules, which bind interleukin-6 (IL-6 ) and neutralise its biological effects. Use of binding members for IL-6 in medical treatment e.g. for treating inflammatory diseases and tumours associated with IL-6.Type: ApplicationFiled: June 30, 2017Publication date: June 14, 2018Inventors: Simon Charles Cruwys, Steven Godfrey Lane, Philip Mallinder
-
Publication number: 20160096895Abstract: This invention relates to binding members, especially antibody molecules, specific for interleukin 1 receptor 1 (IL-1R1). For example, isolated binding members specific for IL-1R1 which competes with IL-1 and IL-1Ra for binding to IL-1R1 and binds Il-1R1 with a KD of 10 pM or less when measured by Kinexa™. The binding members are useful for, inter alia, treatment of disorders mediated by IL-1R1 including rheumatoid arthritis, asthma and chronic obstructive pulmonary disease (COPD).Type: ApplicationFiled: October 23, 2015Publication date: April 7, 2016Inventors: JAMIE IAIN CAMPBELL, DUNCAN JAMES COCHRANE, DONNA KIRSTY FINCH, MARIA ANASTASIA TERESA GROVES, DAVID CHRISTOPHER LOWE, SIMON CHARLES CRUWYS
-
Patent number: 9200074Abstract: This invention relates to binding members, especially antibody molecules, specific for interleukin 1 receptor 1 (IL-1R1). For example, isolated binding members specific for IL-1R1 which competes with IL-1 and IL-1Ra for binding to IL-1R1 and binds Il-1R1 with a KD of 10 pM or less when measured by Kinexa™. The binding members are useful for, inter alia, treatment of disorders mediated by IL-1R1 including rheumatoid arthritis, asthma and chronic obstructive pulmonary disease (COPD).Type: GrantFiled: April 16, 2014Date of Patent: December 1, 2015Assignee: MEDIMMUNE LIMITEDInventors: Jamie Iain Campbell, Duncan James Cochrane, Donna Kirsty Finch, Maria Anastasia Teresa Groves, David Christopher Lowe, Simon Charles Cruwys
-
Publication number: 20150197568Abstract: Binding members, e.g. human antibody molecules, which bind interleukin-6 (IL-6) and neutralise its biological effects. Use of binding members for IL-6 in medical treatment e.g. for treating inflammatory diseases and tumours associated with IL-6.Type: ApplicationFiled: April 1, 2015Publication date: July 16, 2015Inventors: Simon Charles Cruwys, Steven Godfrey Lane, Philip Mallinder
-
Patent number: 9005620Abstract: Binding members, e.g. human antibody molecules, which bind interleukin-6 (IL-6) and neutralize its biological effects. Use of binding members for IL-6 in medical treatment e.g. for treating inflammatory diseases and tumors associated with IL-6.Type: GrantFiled: May 25, 2012Date of Patent: April 14, 2015Assignee: MedImmune LimitedInventors: Simon Charles Cruwys, Steven Godfrey Lane, Philip Mallinder
-
Publication number: 20140212429Abstract: This invention relates to binding members, especially antibody molecules, specific for interleukin 1 receptor 1 (IL-1R1). For example, isolated binding members specific for IL-1R1 which competes with IL-1 and IL-1Ra for binding to IL-1R1 and binds Il-1R1 with a KD of 10 pM or less when measured by Kinexa™. The binding members are useful for, inter alia, treatment of disorders mediated by IL-1R1 including rheumatoid arthritis, asthma and chronic obstructive pulmonary disease (COPD).Type: ApplicationFiled: April 16, 2014Publication date: July 31, 2014Applicant: MEDIMMUNE LIMITEDInventors: JAMIE IAIN CAMPBELL, DUNCAN JAMES COCHRANE, DONNA KIRSTY FINCH, MARIA ANASTASIA TERESA GROVES, DAVID CHRISTOPHER LOWE, SIMON CHARLES CRUWYS
-
Patent number: 8741604Abstract: This invention relates to binding members, especially antibody molecules, specific for interleukin 1 receptor 1 (IL-1R1). For example, isolated binding members specific for IL-1R1 which competes with IL-1 and IL-1Ra for binding to IL-1R1 and binds Il-1R1 with a KD of 10 pM or less when measured by Kinexa™. The binding members are useful for, inter alia, treatment of disorders mediated by IL-1R1 including rheumatoid arthritis, asthma and chronic obstructive pulmonary disease (COPD).Type: GrantFiled: September 14, 2012Date of Patent: June 3, 2014Assignee: Medimmune LimitedInventors: Jamie Iain Campbell, Duncan James Cochrane, Donna Kirsty Finch, Maria Anastasia Teresa Groves, David Christopher Lowe, Simon Charles Cruwys
-
Publication number: 20130078717Abstract: This invention relates to binding members, especially antibody molecules, specific for interleukin 1 receptor 1 (IL-1R1). For example, isolated binding members specific for IL-1R1 which competes with IL-1 and IL-1Ra for binding to IL-1R1 and binds Il-1R1 with a KD of 10 pM or less when measured by Kinexa™. The binding members are useful for, inter alia, treatment of disorders mediated by IL-1R1 including rheumatoid arthritis, athma and chronic obstructive pulmonary disease (COPD).Type: ApplicationFiled: September 14, 2012Publication date: March 28, 2013Applicant: MedImmune LimitedInventors: Jamie Iain CAMPBELL, Duncan James Cochrane, Donna Kirsty Finch, Maria Anastasia Teresa Groves, David Christopher Lowe, Simon Charles Cruwys
-
Publication number: 20120301462Abstract: Binding members, e.g. human antibody molecules, which bind interleukin-6 (IL-6) and neutralise its biological effects. Use of binding members for IL-6 in medical treatment e.g. for treating inflammatory diseases and tumours associated with IL-6.Type: ApplicationFiled: May 25, 2012Publication date: November 29, 2012Applicant: MedImmune LimitedInventors: Simon Charles Cruwys, Steven Godfrey Lane, Philip Mallinder
-
Patent number: 8298533Abstract: This invention relates to binding members, especially antibody molecules, specific for interleukin 1 receptor 1 (IL-1R1). For example, isolated binding members specific for IL-1R1 which competes with IL-1 and IL-1Ra for binding to IL-1R1 and binds Il-1R1 with a KD of 10 pM or less when measured by Kinexa™. The binding members are useful for, inter alia, treatment of disorders mediated by IL-1R1 including rheumatoid arthritis, asthma and chronic obstructive pulmonary disease (COPD).Type: GrantFiled: November 5, 2009Date of Patent: October 30, 2012Assignee: MedImmune LimitedInventors: Jamie Iain Campbell, Duncan James Cochrane, Donna Kirsty Finch, Maria Anastasia Teresa Groves, David Christopher Lowe, Simon Charles Cruwys
-
Patent number: 8198414Abstract: Binding members, e.g. human antibody molecules, which bind interleukin-6 (IL-6) and neutralize its biological effects. Use of binding members for IL-6 in medical treatment e.g. for treating inflammatory diseases and tumors associated with IL-6.Type: GrantFiled: November 30, 2007Date of Patent: June 12, 2012Assignee: MedImmune LimitedInventors: Simon Charles Cruwys, Steven Godfrey Lane, Philip Mallinder
-
Publication number: 20100221257Abstract: This invention relates to binding members, especially antibody molecules, specific for interleukin 1 receptor 1 (IL-1R1). For example, isolated binding members specific for IL-1R1 which competes with IL-1 and IL-1Ra for binding to IL-1R1 and binds Il-1R1 with a KD of 10 pM or less when measured by Kinexa™. The binding members are useful for, inter alia, treatment of disorders mediated by IL-1R1 including rheumatoid arthritis, athma and chronic obstructive pulmonary disease (COPD).Type: ApplicationFiled: November 5, 2009Publication date: September 2, 2010Applicant: MEDIMMUNE LIMITEDInventors: Jamie Iain Campbell, Duncan James Cochrane, Donna Kirsty Finch, Maria Anastasia Teresa Groves, David Christopher Lowe, Simon Charles Cruwys
-
Publication number: 20080188401Abstract: Binding members, e.g. human antibody molecules, which bind interleukin-6 (IL-6) and neutralise its biological effects. Use of binding members for IL-6 in medical treatment e.g. for treating inflammatory diseases and tumours associated with IL-6.Type: ApplicationFiled: November 30, 2007Publication date: August 7, 2008Inventors: Simon Charles Cruwys, Steven Godfrey Lane, Philip Mallinder
